PuSH - Publication Server of Helmholtz Zentrum München

Serr, I. ; Weigmann, B.* ; Franke, R.K. ; Daniel, C.

Treg vaccination in autoimmune type 1 diabetes.

Biodrugs 28, 7-16 (2014)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Foxp3(+) regulatory T (Treg) cells are critical contributors to the establishment and maintenance of immunological self-tolerance. Autoimmune type 1 diabetes (T1D) is characterized by the loss of self-tolerance to the insulin-producing β cells in the pancreas and the destruction of β cells, resulting in the development of chronic hyperglycemia at diagnosis. The application of strong-agonistic T-cell receptor ligands provided under subimmunogenic conditions functions as a critical means for the efficient de novo conversion of naive CD4(+) T cells into Foxp3(+) Treg cells. The specific induction of Treg cells upon supply of strong-agonistic variants of certain self-antigens could therefore function as a critical instrument in order to achieve safe and specific prevention of autoimmunity such as T1D via the restoration of self-tolerance. Such immunotherapeutic strategies are being developed, and in the case of T1D aim to restrict autoimmunity and β-cell destruction. In this review, we discuss the requirements and opportunities for Treg-based tolerance approaches with the goal of interfering with autoimmune T1D.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Regulatory T-cells; Lymphoid-system Mice; Ligase Cbl-b; Foxp3 Expression; In-vivo; Nod Mice; Immunodominant Epitope; Peripheral-blood; Immune-responses; Structural Basis
ISSN (print) / ISBN 1173-8804
e-ISSN 1179-190X
Journal BioDrugs
Quellenangaben Volume: 28, Issue: 1, Pages: 7-16 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Auckland
Reviewing status